Rege Nephro Co., Ltd.

About Rege Nephro Co., Ltd.

Regenephro Co., Ltd. is a global leader leveraging iPS cell technology to innovate treatment options for intractable diseases of the kidney, liver, and pancreas, aiming to create a future where people worldwide are free from suffering due to illness.

Products & Services

iPS Cell Technology-Based Treatments:Developing innovative treatment options for intractable diseases of the kidney, liver, and pancreas using iPS cell technology.

Tamibarotene:Designated as an orphan drug for autosomal dominant polycystic kidney disease.

Specialties

iPS Cell Technology Treatment of Intractable Diseases (Kidney, Liver, Pancreas) Orphan Drug Development

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 22500000000 MR: - FA: 22.5 billion yen FAN: 22500000000	D: 2024-10-07 FD: 2024-10-07	20 investors

Series B Latest

2024-10-07

$22.5B

20 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

長

長谷川浩彦

Executive Officer and Reliability Assurance Director

中

中野毅

Executive Officer, Head of Research and Development

小

小林義史

Executive Officer and Production Director

山

山口勝久

Director/CFO and Head of Management Department

森

森中紹文

Representative Director CEO

長

長船健二

Director and Chief Scientific Advisor (Founder) and Professor at Kyoto University iPS Cell Institute

View 13 more team members with Pro

Unlock Full Team Directory

Recent News